D
Anika Therapeutics, Inc.
ANIK
$15.03
$0.000.00%
D
Sell
3/20/2025Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to D- from E+ on 3/20/2025 due to a noticeable increase in the growth index, solvency index and volatility index. EBIT increased 99.6% from -$24.92M to -$100, and earnings per share increased from -$2.03 to -$1.5.
Anika Therapeutics, Inc. (ANIK) was upgraded to D- from E+ on 3/20/2025 due to a noticeable increase in the growth index, solvency index and volatility index. EBIT increased 99.6% from -$24.92M to -$100, and earnings per share increased from -$2.03 to -$1.5.
E
Sell
3/14/2025Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D- on 3/14/2025 due to a decline in the volatility index.
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D- on 3/14/2025 due to a decline in the volatility index.
D
Sell
2/24/2025Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to D- from E+ on 2/24/2025 due to an increase in the volatility index and total return index.
Anika Therapeutics, Inc. (ANIK) was upgraded to D- from E+ on 2/24/2025 due to an increase in the volatility index and total return index.
E
Sell
2/5/2025Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D- on 2/5/2025 due to a decline in the volatility index and total return index.
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D- on 2/5/2025 due to a decline in the volatility index and total return index.
D
Sell
1/21/2025Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to D- from E+ on 1/21/2025 due to an increase in the volatility index.
Anika Therapeutics, Inc. (ANIK) was upgraded to D- from E+ on 1/21/2025 due to an increase in the volatility index.
E
Sell
1/6/2025Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D- on 1/6/2025 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 3.7 to 3.56.
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D- on 1/6/2025 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 3.7 to 3.56.
D
Sell
1/10/2024Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to D- from E+ on 1/10/2024 due to an increase in the total return index, solvency index and volatility index.
Anika Therapeutics, Inc. (ANIK) was upgraded to D- from E+ on 1/10/2024 due to an increase in the total return index, solvency index and volatility index.
E
Sell
12/5/2023Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D- on 12/5/2023 due to a decline in the volatility index and valuation index.
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D- on 12/5/2023 due to a decline in the volatility index and valuation index.
D
Sell
11/17/2023Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to D- from E+ on 11/17/2023 due to an increase in the valuation index and volatility index.
Anika Therapeutics, Inc. (ANIK) was upgraded to D- from E+ on 11/17/2023 due to an increase in the valuation index and volatility index.
E
Sell
6/21/2023Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D- on 6/21/2023 due to a decline in the volatility index.
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D- on 6/21/2023 due to a decline in the volatility index.
D
Sell
6/6/2023Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to D- from E+ on 6/6/2023 due to an increase in the volatility index and total return index.
Anika Therapeutics, Inc. (ANIK) was upgraded to D- from E+ on 6/6/2023 due to an increase in the volatility index and total return index.
E
Sell
5/18/2023Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D on 5/18/2023 due to a substantial decline in the efficiency index and volatility index. Net income declined 110.88% from -$4.91M to -$10.35M, and total capital declined 2.68% from $316.45M to $307.97M.
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D on 5/18/2023 due to a substantial decline in the efficiency index and volatility index. Net income declined 110.88% from -$4.91M to -$10.35M, and total capital declined 2.68% from $316.45M to $307.97M.
D
Sell
3/17/2023Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to D from D- on 3/17/2023 due to a substantial increase in the efficiency index, solvency index and total return index. Total capital increased 0.13% from $316.04M to $316.45M.
Anika Therapeutics, Inc. (ANIK) was upgraded to D from D- on 3/17/2023 due to a substantial increase in the efficiency index, solvency index and total return index. Total capital increased 0.13% from $316.04M to $316.45M.
D
Sell
3/14/2023Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
Anika Therapeutics, Inc. (ANIK) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Anika Therapeutics, Inc. (ANIK) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the growth index and solvency index. EBIT declined 71.49% from -$3.38M to -$5.8M, earnings per share declined from -$0.2 to -$0.29, and operating cash flow declined 12.27% from $3.09M to $2.71M.
Anika Therapeutics, Inc. (ANIK) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the growth index and solvency index. EBIT declined 71.49% from -$3.38M to -$5.8M, earnings per share declined from -$0.2 to -$0.29, and operating cash flow declined 12.27% from $3.09M to $2.71M.
D
Sell
5/16/2022Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to D from E+ on 05/16/2022.
Anika Therapeutics, Inc. (ANIK) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D on 5/13/2022 due to a major decline in the total return index, volatility index and solvency index.
Anika Therapeutics, Inc. (ANIK) was downgraded to E+ from D on 5/13/2022 due to a major decline in the total return index, volatility index and solvency index.
D
Sell
11/23/2021Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to D from D- on 11/23/2021.
Anika Therapeutics, Inc. (ANIK) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to D- from D+ on 11/8/2021 due to a significant decline in the efficiency index, valuation index and total return index. Net income declined 91.46% from $6.53M to $558.
Anika Therapeutics, Inc. (ANIK) was downgraded to D- from D+ on 11/8/2021 due to a significant decline in the efficiency index, valuation index and total return index. Net income declined 91.46% from $6.53M to $558.
D
Sell
6/1/2021Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to D+ from D on 6/1/2021 due to a noticeable increase in the total return index, solvency index and growth index. Earnings per share increased from -$1.0967 to $0.1979, and total revenue increased 4.91% from $32.69M to $34.29M.
Anika Therapeutics, Inc. (ANIK) was upgraded to D+ from D on 6/1/2021 due to a noticeable increase in the total return index, solvency index and growth index. Earnings per share increased from -$1.0967 to $0.1979, and total revenue increased 4.91% from $32.69M to $34.29M.
D
Sell
3/5/2021Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to D from D+ on 3/5/2021 due to a noticeable decline in the efficiency index, growth index and solvency index. Net income declined 144.21% from -$6.41M to -$15.66M, earnings per share declined from -$0.4513 to -$1.0967, and operating cash flow declined 55.89% from $5.87M to $2.59M.
Anika Therapeutics, Inc. (ANIK) was downgraded to D from D+ on 3/5/2021 due to a noticeable decline in the efficiency index, growth index and solvency index. Net income declined 144.21% from -$6.41M to -$15.66M, earnings per share declined from -$0.4513 to -$1.0967, and operating cash flow declined 55.89% from $5.87M to $2.59M.
D
Sell
11/9/2020Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to D+ from C- on 11/9/2020 due to a large decline in the valuation index, efficiency index and total return index. Total capital declined 8.15% from $361.95M to $332.44M.
Anika Therapeutics, Inc. (ANIK) was downgraded to D+ from C- on 11/9/2020 due to a large decline in the valuation index, efficiency index and total return index. Total capital declined 8.15% from $361.95M to $332.44M.
C
Hold
8/27/2020Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to C- from D+ on 8/27/2020 due to an increase in the total return index and volatility index.
Anika Therapeutics, Inc. (ANIK) was upgraded to C- from D+ on 8/27/2020 due to an increase in the total return index and volatility index.
D
Sell
8/7/2020Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to D+ from C- on 8/7/2020 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.4 to -$0.5429, net income declined 233.06% from $5.79M to -$7.71M, and EBIT declined 163.53% from $5.42M to -$3.44M.
Anika Therapeutics, Inc. (ANIK) was downgraded to D+ from C- on 8/7/2020 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.4 to -$0.5429, net income declined 233.06% from $5.79M to -$7.71M, and EBIT declined 163.53% from $5.42M to -$3.44M.
C
Hold
7/15/2020Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to C- from D+ on 7/15/2020 due to an increase in the volatility index.
Anika Therapeutics, Inc. (ANIK) was upgraded to C- from D+ on 7/15/2020 due to an increase in the volatility index.
D
Sell
5/26/2020Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to D+ from C- on 5/26/2020 due to a decline in the total return index, growth index and valuation index. Operating cash flow declined 91.98% from $13.02M to $1.05M, and EBIT declined 56.96% from $7.75M to $3.33M.
Anika Therapeutics, Inc. (ANIK) was downgraded to D+ from C- on 5/26/2020 due to a decline in the total return index, growth index and valuation index. Operating cash flow declined 91.98% from $13.02M to $1.05M, and EBIT declined 56.96% from $7.75M to $3.33M.
C
Hold
4/28/2020Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to C- from C on 4/28/2020 due to a major decline in the total return index, volatility index and growth index. Earnings per share declined from $0.64 to $0.2774, and EBIT declined 35.7% from $12.05M to $7.75M.
Anika Therapeutics, Inc. (ANIK) was downgraded to C- from C on 4/28/2020 due to a major decline in the total return index, volatility index and growth index. Earnings per share declined from $0.64 to $0.2774, and EBIT declined 35.7% from $12.05M to $7.75M.
C
Hold
10/30/2019Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to C from C+ on 10/30/2019 due to a noticeable decline in the growth index and efficiency index. Earnings per share declined from $0.67 to $0.64, net income declined 2.49% from $9.44M to $9.2M, and total revenue declined 2.37% from $30.42M to $29.7M.
Anika Therapeutics, Inc. (ANIK) was downgraded to C from C+ on 10/30/2019 due to a noticeable decline in the growth index and efficiency index. Earnings per share declined from $0.67 to $0.64, net income declined 2.49% from $9.44M to $9.2M, and total revenue declined 2.37% from $30.42M to $29.7M.
C
Hold
10/29/2019Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to C+ from C on 10/29/2019 due to a significant increase in the growth index, total return index and volatility index. Earnings per share increased from $0.31 to $0.67, EBIT increased 106.75% from $5.76M to $11.92M, and total revenue increased 23.04% from $24.72M to $30.42M.
Anika Therapeutics, Inc. (ANIK) was upgraded to C+ from C on 10/29/2019 due to a significant increase in the growth index, total return index and volatility index. Earnings per share increased from $0.31 to $0.67, EBIT increased 106.75% from $5.76M to $11.92M, and total revenue increased 23.04% from $24.72M to $30.42M.
C
Hold
7/25/2019Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to C from C- on 7/25/2019 due to an increase in the total return index and volatility index.
Anika Therapeutics, Inc. (ANIK) was upgraded to C from C- on 7/25/2019 due to an increase in the total return index and volatility index.
C
Hold
5/8/2019Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to C- from D+ on 5/8/2019 due to a substantial increase in the valuation index, growth index and efficiency index. Total capital increased 10.91% from $263.61M to $292.38M.
Anika Therapeutics, Inc. (ANIK) was upgraded to C- from D+ on 5/8/2019 due to a substantial increase in the valuation index, growth index and efficiency index. Total capital increased 10.91% from $263.61M to $292.38M.
D
Sell
11/14/2018Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to D+ from C- on 11/14/2018 due to a noticeable decline in the growth index and efficiency index. Net income declined 24.7% from $10.09M to $7.6M, EBIT declined 23.77% from $11.25M to $8.57M, and earnings per share declined from $0.68 to $0.53.
Anika Therapeutics, Inc. (ANIK) was downgraded to D+ from C- on 11/14/2018 due to a noticeable decline in the growth index and efficiency index. Net income declined 24.7% from $10.09M to $7.6M, EBIT declined 23.77% from $11.25M to $8.57M, and earnings per share declined from $0.68 to $0.53.
C
Hold
8/2/2018Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to C- from D+ on 8/2/2018 due to an increase in the growth index, valuation index and volatility index. EBIT increased 789.09% from -$1.63M to $11.25M, earnings per share increased from -$0.46 to $0.68, and total revenue increased 43.66% from $21.26M to $30.55M.
Anika Therapeutics, Inc. (ANIK) was upgraded to C- from D+ on 8/2/2018 due to an increase in the growth index, valuation index and volatility index. EBIT increased 789.09% from -$1.63M to $11.25M, earnings per share increased from -$0.46 to $0.68, and total revenue increased 43.66% from $21.26M to $30.55M.
D
Sell
6/20/2018Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to D+ from C- on 6/20/2018 due to a noticeable decline in the total return index, volatility index and valuation index.
Anika Therapeutics, Inc. (ANIK) was downgraded to D+ from C- on 6/20/2018 due to a noticeable decline in the total return index, volatility index and valuation index.
C
Hold
5/18/2018Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to C- from C on 5/18/2018 due to a major decline in the growth index, valuation index and volatility index. Earnings per share declined from $0.5278 to -$0.46, EBIT declined 116.78% from $9.73M to -$1.63M, and total revenue declined 27.64% from $29.39M to $21.26M.
Anika Therapeutics, Inc. (ANIK) was downgraded to C- from C on 5/18/2018 due to a major decline in the growth index, valuation index and volatility index. Earnings per share declined from $0.5278 to -$0.46, EBIT declined 116.78% from $9.73M to -$1.63M, and total revenue declined 27.64% from $29.39M to $21.26M.
C
Hold
5/3/2018Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to C from C+ on 5/3/2018 due to a major decline in the total return index, volatility index and efficiency index.
Anika Therapeutics, Inc. (ANIK) was downgraded to C from C+ on 5/3/2018 due to a major decline in the total return index, volatility index and efficiency index.
C
Hold
11/28/2017Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to C+ from B- on 11/28/2017 due to a noticeable decline in the total return index and valuation index.
Anika Therapeutics, Inc. (ANIK) was downgraded to C+ from B- on 11/28/2017 due to a noticeable decline in the total return index and valuation index.
B
Buy
11/13/2017Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to B- from C+ on 11/13/2017 due to an increase in the total return index and valuation index.
Anika Therapeutics, Inc. (ANIK) was upgraded to B- from C+ on 11/13/2017 due to an increase in the total return index and valuation index.
C
Hold
10/27/2017Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to C+ from B- on 10/27/2017 due to a substantial decline in the growth index, valuation index and efficiency index. EBIT declined 42.07% from $17.73M to $10.27M, earnings per share declined from $0.76 to $0.46, and net income declined 39.42% from $11.37M to $6.89M.
Anika Therapeutics, Inc. (ANIK) was downgraded to C+ from B- on 10/27/2017 due to a substantial decline in the growth index, valuation index and efficiency index. EBIT declined 42.07% from $17.73M to $10.27M, earnings per share declined from $0.76 to $0.46, and net income declined 39.42% from $11.37M to $6.89M.
B
Buy
8/21/2017Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to B- from C+ on 8/21/2017 due to a significant increase in the growth index, valuation index and volatility index. EBIT increased 121.41% from $8.01M to $17.73M, earnings per share increased from $0.37 to $0.76, and total revenue increased 43.09% from $23.39M to $33.46M.
Anika Therapeutics, Inc. (ANIK) was upgraded to B- from C+ on 8/21/2017 due to a significant increase in the growth index, valuation index and volatility index. EBIT increased 121.41% from $8.01M to $17.73M, earnings per share increased from $0.37 to $0.76, and total revenue increased 43.09% from $23.39M to $33.46M.
C
Hold
7/7/2017Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to C+ from C on 7/7/2017 due to an increase in the total return index and volatility index.
Anika Therapeutics, Inc. (ANIK) was upgraded to C+ from C on 7/7/2017 due to an increase in the total return index and volatility index.
C
Hold
6/5/2017Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to C from C+ on 6/5/2017 due to a substantial decline in the total return index, growth index and volatility index. EBIT declined 37.16% from $12.74M to $8.01M, earnings per share declined from $0.5399 to $0.37, and total revenue declined 18.59% from $28.73M to $23.39M.
Anika Therapeutics, Inc. (ANIK) was downgraded to C from C+ on 6/5/2017 due to a substantial decline in the total return index, growth index and volatility index. EBIT declined 37.16% from $12.74M to $8.01M, earnings per share declined from $0.5399 to $0.37, and total revenue declined 18.59% from $28.73M to $23.39M.
C
Hold
3/6/2017Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to C+ from B- on 3/6/2017 due to a decline in the total return index.
Anika Therapeutics, Inc. (ANIK) was downgraded to C+ from B- on 3/6/2017 due to a decline in the total return index.
B
Buy
2/27/2017Downgrade
Anika Therapeutics, Inc. (ANIK) was downgraded to B- from B on 2/27/2017 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 48.35% from $11.31M to $5.84M, net income declined 9.68% from $8.95M to $8.09M, and earnings per share declined from $0.59 to $0.5399.
Anika Therapeutics, Inc. (ANIK) was downgraded to B- from B on 2/27/2017 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 48.35% from $11.31M to $5.84M, net income declined 9.68% from $8.95M to $8.09M, and earnings per share declined from $0.59 to $0.5399.
B
Buy
1/31/2017Upgraded
Anika Therapeutics, Inc. (ANIK) was upgraded to B from B- on 1/31/2017 due to a noticeable increase in the growth index and volatility index. Operating cash flow increased 1,191.03% from -$1.04M to $11.31M, earnings per share increased from $0.57 to $0.59, and EBIT increased 1.63% from $13.47M to $13.69M.
Anika Therapeutics, Inc. (ANIK) was upgraded to B from B- on 1/31/2017 due to a noticeable increase in the growth index and volatility index. Operating cash flow increased 1,191.03% from -$1.04M to $11.31M, earnings per share increased from $0.57 to $0.59, and EBIT increased 1.63% from $13.47M to $13.69M.
B
Buy
9/6/2016Downgrade
Anika Therapeutics Inc. (ANIK) was downgraded to B- from B on 9/6/2016 due to a decline in the growth index and volatility index. Operating cash flow declined 113.5% from $7.68M to -$1.04M.
Anika Therapeutics Inc. (ANIK) was downgraded to B- from B on 9/6/2016 due to a decline in the growth index and volatility index. Operating cash flow declined 113.5% from $7.68M to -$1.04M.
B
Buy
4/6/2016Upgraded
Anika Therapeutics Inc. (ANIK) was upgraded to B from B- on 4/6/2016 due to a large increase in the total return index, volatility index and valuation index.
Anika Therapeutics Inc. (ANIK) was upgraded to B from B- on 4/6/2016 due to a large increase in the total return index, volatility index and valuation index.
B
Buy
3/11/2016Downgrade
Anika Therapeutics Inc. (ANIK) was downgraded to B- from B+ on 3/11/2016 due to a significant decline in the volatility index and valuation index.
Anika Therapeutics Inc. (ANIK) was downgraded to B- from B+ on 3/11/2016 due to a significant decline in the volatility index and valuation index.
B
Buy
2/12/2016Downgrade
Anika Therapeutics Inc. (ANIK) was downgraded to B+ from A- on 2/12/2016 due to a decline in the valuation index.
Anika Therapeutics Inc. (ANIK) was downgraded to B+ from A- on 2/12/2016 due to a decline in the valuation index.
A
Buy
1/28/2016Upgraded
Anika Therapeutics Inc. (ANIK) was upgraded to A- from B+ on 1/28/2016 due to an increase in the valuation index.
Anika Therapeutics Inc. (ANIK) was upgraded to A- from B+ on 1/28/2016 due to an increase in the valuation index.
B
Buy
1/12/2016Downgrade
Anika Therapeutics Inc. (ANIK) was downgraded to B+ from A- on 1/12/2016 due to a decline in the total return index.
Anika Therapeutics Inc. (ANIK) was downgraded to B+ from A- on 1/12/2016 due to a decline in the total return index.
A
Buy
12/28/2015Upgraded
Anika Therapeutics Inc. (ANIK) was upgraded to A- from B+ on 12/28/2015 due to an increase in the total return index, volatility index and valuation index.
Anika Therapeutics Inc. (ANIK) was upgraded to A- from B+ on 12/28/2015 due to an increase in the total return index, volatility index and valuation index.
B
Buy
8/6/2015Upgraded
Anika Therapeutics Inc. (ANIK) was upgraded to B+ from B on 8/6/2015 due to a substantial increase in the growth index. Operating cash flow increased 173.61% from $3.98M to $10.9M, EBIT increased 125.79% from $5.5M to $12.43M, and earnings per share increased from $0.23 to $0.51.
Anika Therapeutics Inc. (ANIK) was upgraded to B+ from B on 8/6/2015 due to a substantial increase in the growth index. Operating cash flow increased 173.61% from $3.98M to $10.9M, EBIT increased 125.79% from $5.5M to $12.43M, and earnings per share increased from $0.23 to $0.51.
B
Buy
5/6/2015Downgrade
Anika Therapeutics Inc. (ANIK) was downgraded to B from A- on 5/6/2015 due to a significant decline in the growth index and valuation index. Operating cash flow declined 73% from $14.76M to $3.98M, earnings per share declined from $0.5139 to $0.23, and EBIT declined 54.46% from $12.09M to $5.5M.
Anika Therapeutics Inc. (ANIK) was downgraded to B from A- on 5/6/2015 due to a significant decline in the growth index and valuation index. Operating cash flow declined 73% from $14.76M to $3.98M, earnings per share declined from $0.5139 to $0.23, and EBIT declined 54.46% from $12.09M to $5.5M.
A
Buy
3/13/2015Upgraded
Anika Therapeutics Inc. (ANIK) was upgraded to A- from B+ on 3/13/2015 due to a large increase in the growth index, efficiency index and valuation index. Operating cash flow increased 200.94% from $4.9M to $14.76M, earnings per share increased from $0.4 to $0.5139, and net income increased 26.66% from $6.17M to $7.82M.
Anika Therapeutics Inc. (ANIK) was upgraded to A- from B+ on 3/13/2015 due to a large increase in the growth index, efficiency index and valuation index. Operating cash flow increased 200.94% from $4.9M to $14.76M, earnings per share increased from $0.4 to $0.5139, and net income increased 26.66% from $6.17M to $7.82M.
B
Buy
12/16/2014Downgrade
Anika Therapeutics Inc. (ANIK) was downgraded to B+ from A- on 12/16/2014 due to a major decline in the volatility index.
Anika Therapeutics Inc. (ANIK) was downgraded to B+ from A- on 12/16/2014 due to a major decline in the volatility index.
A
Buy
9/15/2014Downgrade
Anika Therapeutics Inc. (ANIK) was downgraded to A- from A on 9/15/2014 due to a major decline in the growth index and total return index. Operating cash flow declined 50.56% from $13.6M to $6.72M, earnings per share declined from $0.97 to $0.6, and EBIT declined 36.31% from $23.87M to $15.2M.
Anika Therapeutics Inc. (ANIK) was downgraded to A- from A on 9/15/2014 due to a major decline in the growth index and total return index. Operating cash flow declined 50.56% from $13.6M to $6.72M, earnings per share declined from $0.97 to $0.6, and EBIT declined 36.31% from $23.87M to $15.2M.
A
Buy
5/7/2014Upgraded
Anika Therapeutics Inc. (ANIK) was upgraded to A from A- on 5/7/2014 due to a noticeable increase in the valuation index, growth index and total return index. EBIT increased 125.48% from $10.59M to $23.87M, earnings per share increased from $0.442 to $0.97, and operating cash flow increased 69.84% from $8.01M to $13.6M.
Anika Therapeutics Inc. (ANIK) was upgraded to A from A- on 5/7/2014 due to a noticeable increase in the valuation index, growth index and total return index. EBIT increased 125.48% from $10.59M to $23.87M, earnings per share increased from $0.442 to $0.97, and operating cash flow increased 69.84% from $8.01M to $13.6M.
A
Buy
4/30/2014Downgrade
Anika Therapeutics Inc. (ANIK) was downgraded to A- from A on 4/30/2014 due to a decline in the valuation index.
Anika Therapeutics Inc. (ANIK) was downgraded to A- from A on 4/30/2014 due to a decline in the valuation index.
A
Buy
4/15/2014Upgraded
Anika Therapeutics Inc. (ANIK) was upgraded to A from A- on 4/15/2014 due to a noticeable increase in the growth index, efficiency index and solvency index. Debt to equity declined from 0.07 to 0, EBIT increased 39.85% from $7.57M to $10.59M, and net income increased 34.23% from $4.96M to $6.65M.
Anika Therapeutics Inc. (ANIK) was upgraded to A from A- on 4/15/2014 due to a noticeable increase in the growth index, efficiency index and solvency index. Debt to equity declined from 0.07 to 0, EBIT increased 39.85% from $7.57M to $10.59M, and net income increased 34.23% from $4.96M to $6.65M.
NASDAQ
04/01/2025 4:00PM Eastern
Quotes delayed
